Ozmosi | Avutometinib Drug Profile

Product Description

Avutometinib (VS-6766) is a RAF/MEK Clamp that induces inactive complexes of MEK with ARAF, BRAF and CRAF, potentially creating a more complete and durable anti-tumor response through maximal RAS pathway inhibition. (Sourced from: https://www.verastem.com/research/pipeline/)

Mechanisms of Action: MAP2K Inhibitor, RAFk Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: Breakthrough Therapy - Ovarian Cancer
Fast Track - Non-Small-Cell Lung Cancer
Orphan Drug - Ovarian Cancer
Orphan Drug - Pancreatic Cancer
Priority Review - Ovarian Cancer *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: Verastem
Company Location: Eastern America
Company Founding Year: 2010
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Avutometinib

Countries in Clinic: Australia, Belgium, Canada, Denmark, France, Germany, Ireland, Italy, Japan, Netherlands, New Zealand, Poland, South Korea, Spain, United Kingdom, United States

Active Clinical Trial Count: 19

Recent & Upcoming Milestones

Clinical Outcomes Expected - Verastem announced they will present P2 Pancreatic Cancer results in 2Q26 for Avutometinib
Clinical Outcomes Expected - Verastem announced they will present P3 Ovarian Cancer results in 3Q27 for Avutometinib
Clinical Outcomes Reported - Verastem presented P2 Ovarian Cancer results on 2026-04-10 for Avutometinib

Highest Development Phases

Phase 3: Ovarian Cancer

Phase 1: Endometrial Cancer

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success	Latest Trial Update Date	Data Updated
NCT07318324	NCI-2025-09476	P1	Not yet recruiting	Endometrial Cancer	2028-08-01	50%	2026-01-07	Primary Endpoints
NCT06630260	5G-RUBY	P2	Recruiting	Astrocytoma\|Glioblastoma\|Glioma	2029-09-30	12%	2024-11-07	Primary Endpoints\|Start Date\|Treatments
NCT06487221	AAAV0009	P2	Recruiting	Gastrointestinal Cancer	2028-11-30		2024-07-07
NCT06194929	DETERMINE	P2	Recruiting	Melanoma\|Brain Cancer	2028-01-15	12%	2025-12-04
NCT06007924	NCT06007924	P2	Recruiting	Thyroid Cancer	2027-08-16	12%	2023-08-24	Primary Endpoints\|Treatments
NCT06394804	CHAMELEON	P2	Recruiting	Ovarian Cancer	2027-04-01	12%	2024-05-02	Primary Endpoints\|Treatments
NCT05787561	NCT05787561	P2	Recruiting	Oncology Unspecified	2027-03-01	12%	2026-01-28	Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments
NCT05669482	RAMP205	P2	Active, not recruiting	Pancreatic Cancer	2026-08-31	12%	2025-09-03	Primary Endpoints\|Treatments\|Trial Status
NCT05074810	RAMP203	P2	Active, not recruiting	Non-Small-Cell Lung Cancer	2026-06-01	12%	2026-01-13	Primary Completion Date\|Primary Endpoints\|Treatments\|Trial Status
NCT04625270	RAMP 201	P2	Active, not recruiting	Ovarian Cancer\|Serous Cystadenocarcinoma	2024-11-15	12%	2025-01-30	Primary Completion Date\|Primary Endpoints\|Treatments
NCT03681483	NCT03681483	P1	Completed	Non-Small-Cell Lung Cancer	2024-07-08	50%	2024-07-11	Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status
NCT06072781	RAMP 301	P3	Recruiting	Ovarian Cancer	2028-10-15	3%	2024-11-27	Primary Endpoints\|Treatments
2024-516986-35-00	VS-6766-201	P2	Active, not recruiting	Ovarian Cancer	2027-12-31		2025-05-02	Treatments
jRCT2021240021	jRCT2021240021	P2	Not yet recruiting	Ovarian Cancer	2026-12-31	12%
2023-505107-24-00	VS-6766-203	P2	Recruiting	Non-Small-Cell Lung Cancer	2026-02-28		2025-05-02	Treatments
NCT05375994	RAMP204	P2	Active, not recruiting	Non-Small-Cell Lung Cancer	2025-12-24	12%	2025-05-20	Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments
NCT06682572	RAMP201J	P2	Active, not recruiting	Ovarian Cancer	2025-12-01	12%	2025-12-18	Patient Enrollment\|Primary Endpoints\|Treatments\|Trial Status
jRCT2051250070	jRCT2051250070	P3	Recruiting	Ovarian Cancer	2031-02-09
2023-508204-38-00	VS-6766-301	P3	Recruiting	Ovarian Cancer	2030-11-30		2025-05-02	Treatments

Recent News Events

Date	Type	Title
03/19/2026	News Article	Kaida BioPharma Announces Executive Leadership Team to Advance KAD-101, Built for the Ovarian Cancer Gap
03/17/2026	News Article	Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026
03/17/2026	News Article	Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women's Cancers
02/04/2026	News Article	Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Avutometinib

Alternative Names: Avutometinib, vs-6766, vs6766, vs 6766, RO-5126766, RO5126766, RO 5126766 Clinical Status: Active Latest Update: 2026-05-08 Latest Update Note: Clinical Trial Update